ER+/PR+ breast cancer, common and hormone-responsive, offers a better prognosis and is key in treatment research advancements ...

A real-world study showed HER2DX guided treatment changes in approximately 48% of HER2-positive breast cancer cases.

While current FDA-approved PI3Kα inhibitors, such as alpelisib, have demonstrated success in treating hormone receptor-positive (HR+) and HER2-negative ... limited to cell proliferation and ...

Joseph Mossel is the CEO of Ibex Medical Analytics. His career in the tech industry spans more than 20 years, starting off in ...

The company said that patients with advanced HR+/HER2- breast cancer and TNBC still ... is an enzyme that is involved in cell division and proliferation, and is often overexpressed in cancers.

Sorafenib is an oral multikinase inhibitor that inhibits tumor growth and proliferation by interfering ... of sorafenib in patients with HER-2 negative locally advanced or MBC: Trial 1: the ...

LncRNAs and circRNAs are key regulators of gene expression, influencing disease mechanisms and offering potential as ...

By Kolade Adeyemo / Jambar Contributor Breast cancer is one of the most prevalent cancers worldwide, affecting millions of ...

As observed in Table 3, there were significant positive correlations between the Ki67 proliferation index and the presence of HER2 amplification, between the Ki67 proliferation index and molecular ...